-
Something wrong with this record ?
MicroRNAs: Emerging Regulators of Immune-Mediated Diseases
T. Tomankova, M. Petrek, J. Gallo, E. Kriegova,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT11117
MZ0
CEP Register
NLK
Free Medical Journals
from 1997 to 1 year ago
Medline Complete (EBSCOhost)
from 1972-01-01 to 1 year ago
Wiley Online Library (archiv)
from 1997-01-01 to 2012-12-31
Wiley Free Content
from 1997 to 1 year ago
- MeSH
- Atherosclerosis genetics immunology pathology MeSH
- Dermatitis, Atopic genetics immunology pathology MeSH
- Epigenesis, Genetic immunology MeSH
- Inflammatory Bowel Diseases genetics immunology pathology MeSH
- Humans MeSH
- RNA, Messenger genetics immunology MeSH
- MicroRNAs genetics immunology MeSH
- Osteoarthritis genetics immunology pathology MeSH
- Immunity, Innate MeSH
- Psoriasis genetics immunology pathology MeSH
- Arthritis, Rheumatoid genetics immunology pathology MeSH
- RNA Interference immunology MeSH
- Multiple Sclerosis genetics immunology pathology MeSH
- RNA Stability MeSH
- Lupus Erythematosus, Systemic genetics immunology pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
MicroRNAs (miRNAs) represent the most abundant class of regulators of gene expression in humans: they regulate one-third of human protein-coding genes. These small noncoding ∼22-nucleotides (nt)-long RNAs originate by multistep process from miRNA genes localized in the genomic DNA. To date, more than 1420 miRNAs have been identified in humans (miRBase v17). The main mechanism of miRNA action is the posttranscriptional regulation via RNA interference with their target mRNAs. The majority of target mRNAs (more than 80%) undergo degradation after recognition by complementary miRNA; the translational inhibition with little or no influence on mRNA levels has been also reported. Each miRNA may suppress multiple mRNA targets (average ∼200), and at the same time, one mRNA can be targeted by many miRNAs enabling to control a spectrum wide range of cellular processes. Recently, the role of miRNAs in the development of immune cells and the maintenance of immune system homeostasis gained attention, and the involvement of miRNAs in the pathogenesis of several immune system diseases has emerged. This review focuses on the role of miRNAs in autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and psoriasis), inflammatory pathologies of distinct organ (atherosclerosis, osteoarthritis and atopic eczema) and/or systemic locations such as allergy. The role of miRNAs, their predicted and known mRNA targets and description of their actions in physiological immune reactions and in the pathological processes ongoing in immune-mediated human disorders will be discussed. Finally, miRNA-based diagnostics and therapeutic potentials will be highlighted.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15032125
- 003
- CZ-PrNML
- 005
- 20190606100005.0
- 007
- ta
- 008
- 151005s2012 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1365-3083.2011.02650.x $2 doi
- 035 __
- $a (PubMed)21988491
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tománková, Tereza $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $7 xx0199224
- 245 10
- $a MicroRNAs: Emerging Regulators of Immune-Mediated Diseases / $c T. Tomankova, M. Petrek, J. Gallo, E. Kriegova,
- 520 9_
- $a MicroRNAs (miRNAs) represent the most abundant class of regulators of gene expression in humans: they regulate one-third of human protein-coding genes. These small noncoding ∼22-nucleotides (nt)-long RNAs originate by multistep process from miRNA genes localized in the genomic DNA. To date, more than 1420 miRNAs have been identified in humans (miRBase v17). The main mechanism of miRNA action is the posttranscriptional regulation via RNA interference with their target mRNAs. The majority of target mRNAs (more than 80%) undergo degradation after recognition by complementary miRNA; the translational inhibition with little or no influence on mRNA levels has been also reported. Each miRNA may suppress multiple mRNA targets (average ∼200), and at the same time, one mRNA can be targeted by many miRNAs enabling to control a spectrum wide range of cellular processes. Recently, the role of miRNAs in the development of immune cells and the maintenance of immune system homeostasis gained attention, and the involvement of miRNAs in the pathogenesis of several immune system diseases has emerged. This review focuses on the role of miRNAs in autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and psoriasis), inflammatory pathologies of distinct organ (atherosclerosis, osteoarthritis and atopic eczema) and/or systemic locations such as allergy. The role of miRNAs, their predicted and known mRNA targets and description of their actions in physiological immune reactions and in the pathological processes ongoing in immune-mediated human disorders will be discussed. Finally, miRNA-based diagnostics and therapeutic potentials will be highlighted.
- 650 _2
- $a revmatoidní artritida $x genetika $x imunologie $x patologie $7 D001172
- 650 _2
- $a ateroskleróza $x genetika $x imunologie $x patologie $7 D050197
- 650 _2
- $a atopická dermatitida $x genetika $x imunologie $x patologie $7 D003876
- 650 _2
- $a epigeneze genetická $x imunologie $7 D044127
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a přirozená imunita $7 D007113
- 650 _2
- $a idiopatické střevní záněty $x genetika $x imunologie $x patologie $7 D015212
- 650 _2
- $a systémový lupus erythematodes $x genetika $x imunologie $x patologie $7 D008180
- 650 _2
- $a mikro RNA $x genetika $x imunologie $7 D035683
- 650 _2
- $a roztroušená skleróza $x genetika $x imunologie $x patologie $7 D009103
- 650 _2
- $a osteoartróza $x genetika $x imunologie $x patologie $7 D010003
- 650 _2
- $a psoriáza $x genetika $x imunologie $x patologie $7 D011565
- 650 _2
- $a RNA interference $x imunologie $7 D034622
- 650 _2
- $a stabilita RNA $7 D020871
- 650 _2
- $a messenger RNA $x genetika $x imunologie $7 D012333
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Petrek, M $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech RepublicDepartment of Orthopaedics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Gallo, Jiří $u Department of Orthopaedics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0019005
- 700 1_
- $a Kriegová, Eva, $u Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic $d 1968- $7 xx0142572
- 773 0_
- $w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 75, č. 2 (2012), s. 129-141
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21988491 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20190606100142 $b ABA008
- 999 __
- $a ok $b bmc $g 1093001 $s 915251
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 75 $c 2 $d 129-141 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
- GRA __
- $a NT11117 $p MZ0
- LZP __
- $a Pubmed-20151005